Uceris Tablets
Generic name:budesonide
Dosage form: tablet, extended release
Drug class:Glucocorticoids
Medically reviewed by Drugs.com. Last updated on Mar 22, 2022.
On This Page
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Contraindications
- Warnings and Precautions
- Adverse Reactions/Side Effects
- Drug Interactions
- Use In Specific Populations
- Overdosage
- Description
- Clinical Pharmacology
- Nonclinical Toxicology
- Clinical Studies
- References
- How Supplied/Storage and Handling
- Patient Counseling Information
Indications and Usage for Uceris Tablets
UCERIS® extended-release tablets are indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis.
Uceris Tablets Dosage and Administration
Mild to Moderate Ulcerative Colitis
The recommended dosage for the induction of remission in adult patients with active, mild to moderate ulcerative colitis is 9 mg taken orally once daily in the morning with or without food for up to 8 weeks. UCERIS should be swallowed whole and not chewed, crushed or broken.
CYP3A4 Inhibitors
If concomitant administration with ketoconazole, or any other CYP3A4 inhibitor, is indicated, patients should be closely monitored for increased signs and/or symptoms of hypercorticism. Avoid grapefruit juice, which is known to inhibit CYP3A4, when taking UCERIS. In these cases, discontinuation of UCERIS or the CYP3A4 inhibitor should be considered [see Drug Interactions (7) and Clinical Pharmacology (12.3)].
Dosage Forms and Strengths
White, round, biconvex extended-release tablets debossed with “MX9”. Each extended-release tablet contains 9 mg budesonide.
Contraindications
UCERIS is contraindicated in patients with hypersensitivity to budesonide or any of the ingredients of UCERIS. Anaphylactic reactions have occurred with o...
